FDA Approves Revuforj for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

The FDA approved Revuforj, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine ...

NOVEMBER 18, 2024